Last €70.22 EUR
Change Today -0.085 / -0.12%
Volume 188.0
NOTA On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
Frankfurt
SIX Swiss Ex
As of 9:45 AM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by NOVARTIS AG-SPONSORED ADR (NOTA) in the last 6 months

Announced 10/14/14
24.00M for Raze Therapeutics, Inc.
Private Placement

Raze Therapeutics announced that it has received $24 million in its series A round of funding on October 14, 2014. The transaction included participation from new investors, Atlas Venture L.P., MPM Capital, Merck Serono S.A., Investment Arm, Partners Innovation Fund, Astellas Venture Management LLC, and Novartis AG. As part of the round, Ansbert Gadicke of MPM Capital, Nilesh Kumar of Merck Serono S.A., Investment Arm, Reza Halse of Partners Innovation Fund, Jason Rhodes ...
Read More


NOTA's price was unchanged after the transaction was announced on 10/14/14.
Investor / Buyer
Astellas Venture Management LLC
Atlas Venture L.P.
Merck Serono S.A., Investment Arm
MPM Capital
Novartis AG
Partners Innovation Fund
 
Announced 08/18/14
35.00M for Gamida Cell Ltd.
Private Placement

Gamida Cell Ltd. announced that it will receive $35 million in a round of funding from Novartis AG on August 18, 2014. The investor will acquire 15% stake in the company through this transaction. The investor also has an option to fully acquire the company. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord, which is anticipated to be met during 2015. The option, if not exercised, ...
Read More


NOTA's price was unchanged after the transaction was announced on 08/18/14.
Investor / Buyer
Novartis AG
 
Announced 07/28/14
16.00M for Seventh Sense Biosystems, Inc.
Private Placement

Seventh Sense Biosystems, Inc. announced that it will receive $16,467,084 in funding on July 28, 2014. The company will issue common shares, convertible debt and an option, warrant or other right to acquire another security in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. As of August 8, 2014, the company has received $10,467,084 in its first tranche close from eight investors.


NOTA's price was unchanged after the transaction was announced on 07/28/14.
Investor / Buyer
Flagship Ventures
Laboratory Corp. of America Holdings
Novartis AG
Polaris Partners
Siemens Financial Services, Inc.
 
Announced 07/17/14
LTS Lohmann Therapie-Systeme AG
Merger/Acquisition

dievini Hopp BioTech holding GmbH & Co. KG entered into an agreement to acquire additional 67% stake in LTS Lohmann Therapie-Systeme AG from BWK GmbH Unternehmensbeteiligungsgesellschaft and Novartis AG (SWX:NOVN) on July 16, 2014. The transaction is subject to regulatory approvals, other customary conditions and is expected to close in 2014. As of September 8, 2014, Federal Trade Commission approved the transaction. Morgan Stanley Bank AG acted as financial advisor ...
Read More


NOTA's price was unchanged after the transaction was announced on 07/17/14.
Investor / Buyer
dievini Hopp BioTech holding GmbH & Co. KG
Creditor / Lender
BWK GmbH Unternehmensbeteiligungsgesellschaft
Novartis AG
Financial Advisor
Morgan Stanley Bank AG
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOTA:GR €70.22 EUR -0.085

NOTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $102.48 USD +1.26
Merck & Co Inc $56.78 USD +1.26
Pfizer Inc $28.76 USD +0.459
Roche Holding AG SFr.279.40 CHF +1.10
Procter & Gamble Co/The $83.08 USD -1.15
View Industry Companies
 

Industry Analysis

NOTA

Industry Average

Valuation NOTA Industry Range
Price/Earnings 23.8x
Price/Sales 3.6x
Price/Book 3.1x
Price/Cash Flow 24.6x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.